- Home
- UFCS vs PLRX Comparison
UFCS vs PLRX Comparison
Compare UFCS & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- PLRX
- Stock Information
- Founded
- UFCS 1946
- PLRX 2015
- Country
- UFCS United States
- PLRX United States
- Employees
- UFCS N/A
- PLRX N/A
- Industry
- UFCS Property-Casualty Insurers
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- PLRX Health Care
- Exchange
- UFCS Nasdaq
- PLRX Nasdaq
- Market Cap
- UFCS 666.1M
- PLRX 77.3M
- IPO Year
- UFCS N/A
- PLRX 2020
- Fundamental
- Price
- UFCS $27.87
- PLRX $1.44
- Analyst Decision
- UFCS Buy
- PLRX Hold
- Analyst Count
- UFCS 2
- PLRX 10
- Target Price
- UFCS $30.00
- PLRX $9.79
- AVG Volume (30 Days)
- UFCS 133.8K
- PLRX 1.6M
- Earning Date
- UFCS 08-05-2025
- PLRX 08-06-2025
- Dividend Yield
- UFCS 2.36%
- PLRX N/A
- EPS Growth
- UFCS N/A
- PLRX N/A
- EPS
- UFCS 2.54
- PLRX N/A
- Revenue
- UFCS $1,288,423,000.00
- PLRX N/A
- Revenue This Year
- UFCS $11.31
- PLRX N/A
- Revenue Next Year
- UFCS $10.61
- PLRX N/A
- P/E Ratio
- UFCS $10.68
- PLRX N/A
- Revenue Growth
- UFCS 14.59
- PLRX N/A
- 52 Week Low
- UFCS $18.04
- PLRX $1.10
- 52 Week High
- UFCS $31.70
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- UFCS 44.83
- PLRX 55.31
- Support Level
- UFCS $26.95
- PLRX $1.13
- Resistance Level
- UFCS $28.35
- PLRX $1.27
- Average True Range (ATR)
- UFCS 0.64
- PLRX 0.11
- MACD
- UFCS -0.11
- PLRX 0.03
- Stochastic Oscillator
- UFCS 29.81
- PLRX 93.33
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.